ACADIA Pharmaceuticals Gestion
Gestion contrôle des critères 2/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Catherine Owen Adams
Directeur général
n/a
Rémunération totale
| Pourcentage du salaire du PDG | n/a |
| Durée du mandat du directeur général | less than a year |
| Propriété du PDG | n/a |
| Durée moyenne d'occupation des postes de direction | 2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9yrs |
Mises à jour récentes de la gestion
Recent updates
Acadia Pharmaceuticals: Proving The Naysayers Wrong
Nov 11ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Nov 08
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18PDG
Catherine Owen Adams (54 yo)
less than a year
Titularisation
Ms. Catherine E. Owen Adams is CEO & Director of ACADIA Pharmaceuticals Inc. from September 23, 2024. Ms. Owen Adams served as Director of OptiNose US, Inc. since July 2020 until September 24, 2024. She se...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Executive VP & CFO | 3.2yrs | US$2.59m | 0.032% $ 862.3k | |
| Executive VP | 3yrs | US$2.62m | 0.037% $ 1.0m | |
| Consultant | less than a year | US$7.59m | 0.11% $ 3.0m | |
| CEO & Director | less than a year | pas de données | pas de données | |
| VP, Chief Accounting Officer & Corporate Controller | 4.3yrs | pas de données | 0.012% $ 321.5k | |
| Executive VP and Head of Research & Development | less than a year | pas de données | pas de données | |
| Senior Vice President of Technical Development | 2yrs | pas de données | pas de données | |
| Senior Vice President of Investor Relations & Corporate Communications | 1.2yrs | pas de données | pas de données | |
| Executive VP | less than a year | pas de données | pas de données | |
| Senior VP & Head of Sales | 2.8yrs | pas de données | pas de données | |
| Senior VP & Chief People Officer | 2.8yrs | pas de données | pas de données | |
| Senior Vice President of New Product Planning & Strategy | no data | pas de données | pas de données |
2.0yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe de direction de ACAD est considérée comme expérimentée (ancienneté moyenne 2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Director | less than a year | pas de données | pas de données | |
| Independent Director | 16.5yrs | US$392.75k | 0.012% $ 326.0k | |
| Independent Director | 8.9yrs | US$377.75k | 0.062% $ 1.7m | |
| Member of the Scientific and Clinical Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 9yrs | US$387.75k | 0.015% $ 415.1k | |
| Independent Director | 9.7yrs | US$387.75k | 0.021% $ 560.8k | |
| Member of the Scientific and Clinical Advisory Board | no data | pas de données | pas de données | |
| Member of the Scientific and Clinical Advisory Board | no data | pas de données | pas de données | |
| Member of the Scientific and Clinical Advisory Board | no data | pas de données | pas de données | |
| Independent Director | 8.8yrs | US$387.75k | 0.015% $ 399.0k | |
| Independent Chairman of the Board | 11.8yrs | US$432.75k | 0.062% $ 1.7m | |
| Independent Director | 4.2yrs | US$377.75k | 0.014% $ 364.3k |
9.0yrs
Durée moyenne de l'emploi
66yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de ACAD sont considérés comme expérimentés (ancienneté moyenne 9 ans).